The regulatory roles and therapeutic strategies of the solute carrier transporters in cancer metabolism
The Solute Carrier (SLC) family regulates cancer metabolism, supporting proliferation and immune evasion. Key members, such as GLUT1, LAT1, ASCT2, xCT and MCT4, drive metabolic reprogramming and are therapeutic targets. Selective inhibitors like BAY-876 show preclinical efficacy. Combining SLC inhibition with standard therapies may overcome resistance, while personalized strategies and advances in biomarkers and drug delivery are critical for clinical translation.
Authors
- Min He (ORCID: https://orcid.org/0000-0003-0361-8984)
- Jiao Feng
- Tao Ding (ORCID: https://orcid.org/0000-0002-0003-5452)
- XU Weilang
- Xiao Ming Zhang (ORCID: https://orcid.org/0000-0001-5327-8506)
- Xiaoling Xu (ORCID: https://orcid.org/0009-0007-3397-6084)
- Xufan Cai
- Yonghui Dong (ORCID: https://orcid.org/0000-0003-0877-4249)
- Zaiyuan Ye
Institutions
- Zhejiang Chinese Medical University (CN)
- Hangzhou Normal University (CN)
- Zhejiang Shuren University (CN)
- Zhejiang Provincial People's Hospital (CN)
- Hangzhou Medical College (CN)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1038/s41698-025-01198-9
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00